Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer

Cancer Immunology, Immunotherapy

Volumn 56, Issue 12, 2007, Pages 1931-1943

  Butterfield, Lisa H ^a   Ribas, Antoni ^b   Potter, Douglas M ^c   Economou, James S ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alpha fetoprotein; Cancer vaccine; Immunological monitoring; Immunotherapy; T lymphocytes

Indexed keywords

AFP PEPTIDE PULSED AUTOLOGOUS DENDRITIC CELL; ALPHA FETOPROTEIN; CAPECITABINE; CISPLATIN; DENDRITIC CELL VACCINE; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; HLA A2 ANTIGEN; TETRAMER; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MEMORY CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ADULT; AGED; ALPHA-FETOPROTEINS; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; T-LYMPHOCYTES;

EID: 34848815972     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0337-9     Document Type: Article

References (42)

1. Butterfield LH et al (2003) T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9(16 Pt 1):5902-5908
2. Butterfield LH et al (2006) A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12(9):2817-2825
3. Ruoslahti E (1979) Alpha-fetoprotein in cancer and fetal development. Adv Cancer Res 29:275-346
4. Alisa A et al (2005) Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res 11(18):6686-6694
5. Butterfield LH et al (1999) Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59(13):3134-3142
6. Butterfield LH et al (2001) T cell responses to HLA-A*0201- restricted peptides derived from human alpha fetoprotein. J Immunol 166(8):5300-5308
7. Hanke P et al (2002) Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 37(8):949-955
8. Liu Y et al (2006) Hierarchy of AFP-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 177(1):712-721
9. Hamann D et al (1997) Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186(9):1407-1418
10. Sallusto F, Geginat J, Lanzavecchia A (2004), Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22:745-763
11. Sallusto F et al (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):708-712
12. Lee PP (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5(6):677-685
13. Dunbar PR et al (2000) A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 165(11):6644-6652
14. Pittet MJ et al (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190(5):705-715
15. Speiser DE, Cerottini JC, Romero P (2002) Can hTERT peptide (540-548)-specific CD8 T cells recognize and kill tumor cells? Cancer Immun 2:14
16. Pittet MJ et al (2001) Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 7(3 Suppl):796s-803s
17. Kim JW et al (2004) Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 10(15):5101-5110
18. Kim JW, Ferris RL, Whiteside TL (2005) Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res 11(21):7901-7910
19. Meng WS et al (2001) alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 61(24):8782-8786
20. Herr W et al (1996) Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Meth 191(2):131-142
21. Mayer S et al (1996) A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. J Immunol Meth 197(1-2):131-137
22. Huang J et al (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28(3):258-267
23. Appay V et al (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8(4):379-385
24. Smith CL et al (2005) Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 175(12):8431-8437
25. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5(5):397-405
26. Ajuebor MN, Carey JA, Swain MG (2006) CCR5 in T cell-mediated liver diseases: what's going on? J Immunol 177(4):2039-2045
27. Tatsumi T et al (2003) Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 63(15):4481-4489
28. Butterfield LH et al (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9(3):998-1008
29. Ribas A et al (2004) Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27(5):354-367
30. Evdokimova VN et al (2007) AFP specific CD4+ helper T cell responses in healthy donors and HCC patients. J Immunother (in press)
31. Seregni E, Botti C, Bombardieri E (1995) Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms. Anticancer Res 15(4):1491-1499
32. Heydtmann M et al (2006) Detailed analysis of intrahepatic CD8 T cells in the normal and hepatitis C-infected liver reveals differences in specific populations of memory cells with distinct homing phenotypes. J Immunol 177(1):729-738
33. Dumortier H et al (2005) Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function. J Immunol 175(2):855-863
34. Speiser DE et al (2002) In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 32(3):731-741
35. Harari A et al (2005) Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 174(2):1037-1045
36. Beckebaum S, et al (2002) Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 104(2):138-150
37. Ninomiya T et al (1999) Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 31(2):323-331
38. Piccioli D et al (2005) Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 42(1):61-67
39. Bei R et al (1999) Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res 59(21):5471-5474
40. Curtsinger JM, (2005) Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol 175(7):4392-4399
41. Curtsinger JM et al (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174(8):4465-4469
42. Schumacher L et al (2004) Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 27(3):191-200